{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:42:17Z","timestamp":1792420937905,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Joint Funds for the Innovation of Science and Technology of Fujian province","award":["2018Y9032"],"award-info":[{"award-number":["2018Y9032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16491-4","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:07:59Z","timestamp":1784599679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"3","key":"16491_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"16491_CR2","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.3390\/ijms22095019","volume":"22","author":"H Oliveres","year":"2021","unstructured":"Oliveres H, Pes\u00e1ntez D, Maurel J. Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients. Int J Mol Sci. 2021;22(9):5019.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"16491_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12029-024-01152-1","volume":"56","author":"LFL Silva","year":"2024","unstructured":"Silva LFL, Saldanha EF, da Concei\u00e7\u00e3o LD, Noronha MM, da Silva MVM, Peixoto RD. Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis. J Gastrointest Cancer. 2024;56(1):28\u201338.","journal-title":"J Gastrointest Cancer"},{"issue":"7","key":"16491_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669\u201385.","journal-title":"JAMA"},{"key":"16491_CR5","doi-asserted-by":"publisher","first-page":"1398419","DOI":"10.3389\/fphar.2024.1398419","volume":"15","author":"A R\u00edos-Hoyo","year":"2024","unstructured":"R\u00edos-Hoyo A, Monzon\u00eds X, Vidal J, Linares J, Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharmacol. 2024;15:1398419.","journal-title":"Front Pharmacol"},{"issue":"3","key":"16491_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678\u2013700.","journal-title":"J Clin Oncol"},{"issue":"7","key":"16491_CR7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/cancers14071641","volume":"14","author":"MS McCoy","year":"2022","unstructured":"McCoy MS, Wolf S, Struck V, Thomas N, Husman G, Zeuzem S et al. Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis. Cancers (Basel). 2022;14(7):1641.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"16491_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","volume":"20","author":"H Bando","year":"2023","unstructured":"Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2023;20(5):306\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"16491_CR9","doi-asserted-by":"publisher","first-page":"e245635","DOI":"10.1001\/jamanetworkopen.2024.5635","volume":"7","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G, et al. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS\/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open. 2024;7(4):e245635.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"16491_CR10","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/ijms24021702","volume":"24","author":"T Ohishi","year":"2023","unstructured":"Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Current Targeted Therapy for Metastatic Colorectal Cancer. Int J Mol Sci. 2023;24(2):1702.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"16491_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ijc.34632","volume":"153","author":"S Napolitano","year":"2023","unstructured":"Napolitano S, Ciardiello D, De Falco V, Martini G, Martinelli E, Della Corte CM, et al. Panitumumab plus trifluridine\/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. Int J Cancer. 2023;153(8):1520\u20138.","journal-title":"Int J Cancer"},{"issue":"1","key":"16491_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12029-024-01128-1","volume":"56","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Rodrigues ALSO, Priantti JN, Burbano RMR. Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. J Gastrointest Cancer. 2024;56(1):9\u201327.","journal-title":"J Gastrointest Cancer"},{"issue":"8","key":"16491_CR13","doi-asserted-by":"publisher","first-page":"9392","DOI":"10.1002\/cam4.5699","volume":"12","author":"G Martini","year":"2023","unstructured":"Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS\/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Med. 2023;12(8):9392\u2013400.","journal-title":"Cancer Med"},{"issue":"8","key":"16491_CR14","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"16491_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdy526","volume":"30","author":"K Shitara","year":"2019","unstructured":"Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2019;30(2):259\u201365.","journal-title":"Ann Oncol"},{"issue":"10395","key":"16491_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41\u201353.","journal-title":"Lancet"},{"issue":"9863","key":"16491_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u201312.","journal-title":"Lancet"},{"issue":"4","key":"16491_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36(4):350\u20138.","journal-title":"J Clin Oncol"},{"key":"16491_CR19","doi-asserted-by":"publisher","first-page":"102700","DOI":"10.1016\/j.ctrv.2024.102700","volume":"125","author":"D Johnson","year":"2024","unstructured":"Johnson D, Chee CE, Wong W, Lam RCT, Tan IBH, Ma BBY. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions. Cancer Treat Rev. 2024;125:102700.","journal-title":"Cancer Treat Rev"},{"key":"16491_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CMAR.S464831","volume":"16","author":"J Zhong","year":"2024","unstructured":"Zhong J, Liu Y, Fu Q, Huang D, Gong W, Zou J. Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer. Cancer Manag Res. 2024;16:593\u2013602.","journal-title":"Cancer Manag Res"},{"issue":"26","key":"16491_CR21","doi-asserted-by":"publisher","first-page":"e42897","DOI":"10.1097\/MD.0000000000042897","volume":"104","author":"S Ata","year":"2025","unstructured":"Ata S, G\u00fclmez A, K\u00f6\u015feci T, \u00d6zalp \u00d6, \u00c7il T, Bozkurt Duman B. Evaluation of the efficacy of regorafenib treatment by location and RAS mutation in metastatic colon cancer. Med (Baltim). 2025;104(26):e42897.","journal-title":"Med (Baltim)"},{"issue":"3","key":"16491_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Rossini D, Dell\u2019Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5(3):343\u201350.","journal-title":"JAMA Oncol"},{"issue":"9","key":"16491_CR23","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313\u20138.","journal-title":"Ann Oncol"},{"issue":"6","key":"16491_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619\u201329.","journal-title":"Lancet Oncol"},{"key":"16491_CR25","doi-asserted-by":"publisher","first-page":"1363305","DOI":"10.3389\/fonc.2024.1363305","volume":"14","author":"OU Unal","year":"2024","unstructured":"Unal OU, Akay S, Semiz HS, Keser M, Demir G, Capar ZG, et al. Survival outcomes according to the tumor location and prognostic factor in metastatic rectal cancer: a multicenter retrospective cohort study. Front Oncol. 2024;14:1363305.","journal-title":"Front Oncol"},{"key":"16491_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00384-025-04841-w","volume":"40","author":"R Fan","year":"2025","unstructured":"Fan R, Mao C, Zhang J, Dai M, Zhang R, Wang X, et al. Predicting extensive metastasis in postoperative oligometastatic colorectal cancer. Int J Colorectal Dis. 2025;40:53.","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"16491_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41467-024-51536-x","volume":"15","author":"X Xu","year":"2024","unstructured":"Xu X, Ai L, Hu K, Liang L, Lv M, Wang Y, et al. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nat Commun. 2024;15(1):725.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16491-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16491-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16491-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:02:18Z","timestamp":1792418538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16491-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16491"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16491-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board (IRB number: 2019KJTPD030) of Fujian Medical University Union Hospital and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1255"}}